skip to Main Content

IBT Vaccines Receives $3.9 mil. to Advance Development of IBT-V02, the First Multivalent Toxoid Vaccine for MRSA

IBT Vaccines, a wholly owned subsidiary of Integrated Biotherapeutics Inc., announces it has received $3.9 million to advance the development of the IBT-V02 vaccine for Staphylococcus aureus induced recurrent skin and skin structure infections (SSSI). The funding is part of a $48 mil. investment in 8 companies by Novo Holding’s REPAIR Impact Fund, established in 1999 to support the discovery and early development of therapies targeting drug resistant microorganisms. IBT-V02, which is currently in late pre-clinical development, is a unique and potentially first-to-market multivalent toxoid vaccine with broad coverage. S. aureus produces a remarkably large number of toxins that modulate host immune response. The goal is to harness the growing knowledge about its complex relationship with the host to develop effective prophylaxis and immunotherapy for S. aureus/MRSA disease.

“Antibiotic resistant Staphylococcus aureus is a leading cause of morbidity and mortality around the world. This partnership with Novo Holdings REPAIR Impact Fund will prove invaluable in advancing our efforts of delivering a new innovative class of preventive medicines to combat staphylococcal infections and reduce the burden of antibiotic resistance,” said IBT President and CSO M. Javad Aman, PhD.

Drug resistance S. aureus is a major source of drug resistant bacterial infection on the planet.

In August 2019, IBT also was awarded $1.6 mil. by CARB-X, a global partnership lead by Boston University, to evaluate IBT-Vo2’s efficacy against bacterial strains affecting developing and developed nations and to explore the development of freeze-dried powder formulation to permit safe storage of the vaccine in regions that lack reliable cold storage systems.

About IBT:

IBT Vaccines is a wholly owned subsidiary of Integrated Biotherapeutics Inc., a biotechnology company focused on the discovery​ of novel vaccines and therapies for emerging infectious diseases with a pipeline that includes promising candidates for bacterial and viral infections including vaccines for Staphylococcal infections, unique pan-filovirus immunotherapeutics and vaccines, and a variety of other product candidates for emerging pathogens. Located in Rockville, MD, IBT has a close working relationship with United States Government agencies including the National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Cancer Research Institute (NCI), Department of Defense (DOD), United States Army Medical Research Institute of Infection Diseases (USAMRIID) as well as many biotechnology and pharmaceutical companies and academic laboratories.

For further information about Integrated BioTherapeutics or its research service section IBT Bioservices contact:

Haimi Shiferaw

Phone: (240) 778-6513

Email: services@IBTBioservices.com 

Website: http://www.ibtbioservices.com/about/ 

Back To Top
×Close search
Search